India tightens surveillance on semaglutide supply after Interpol flags fake batch | Today’s news

Namit Joshi, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), said: “Indian pharmaceutical manufacturers strictly adhere to local and international regulatory frameworks. As the international alert relates to a foreign entity, domestic generic manufacturers operating through authorized channels are not affected. However, given the growing global demand for GLP-1 therapies, it is imperative that regulators and review patients remain the only healthcare providers who would not controlled. on statutory medical prescriptions and supply networks approved by CDSCO.”